Buying guide
Maestro vs ROSA in 2026
Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.
Key differences
On DEPLOY's record, ROSA is further along: at the commercial stage versus Maestro at the pilot stage, as of 2026.
- Maestro has the lower recorded price.
- ROSA has more verified real-world deployments (2 vs 1).
- Maestro is at the pilot stage; ROSA at the commercial stage.
| Attribute | No image on file | No image on file |
|---|---|---|
| Manufacturer | Moon Surgical | Zimmer Biomet |
| Form factor | surgical | surgical |
| Maturity | pilot | commercial |
| Autonomy | ◐ not independently verified | ◐ not independently verified |
| Availability | internal-onlyenterprise | internal-onlyenterprise |
| Price | $300,000-$800,000 (analyst estimate) | $1,000,000-$1,500,000 (analyst estimate) |
| Capability claims |
|
|
| Brain | — | — |
| Verified deployments | 1Moon Surgical | 2Zimmer Biomet, Zimmer Biomet |
| Privacy practices | — | — |
| Sources on file | 9 | 14 |
Track this matchup
Get told the moment Maestro or ROSA changes. Verified changes only, the second they are real. No press-release noise.
Maestro
ROSA
Editorial summaries
Maestro
Moon Surgical's Maestro is a laparoscopic surgical-assistant platform (it holds and positions instruments and the endoscope alongside the surgeon, not a full master-slave teleoperated replacement system) and the assistive-laparoscopy archetype of DEPLOY's surgical cluster, editorially distinct from the replacement-robotics of Intuitive, Medtronic, and CMR. Its ScoPilot software is shipped AI (NVIDIA Holoscan-powered) for intraoperative scope control.
On regulatory status (a correction worth recording): the Maestro received FDA 510(k) clearance K240598 on June 5, 2024 (not December 2023), and ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan. As enterprise B2B surgical equipment, there is no consumer price.
ROSA
Zimmer Biomet's ROSA (Robotic Surgical Assistant) is a single articulated robotic arm coupled to optical navigation and 2D/3D planning software, and the mid-size, cross-domain archetype of the orthopedic sub-cohort: it spans orthopedics and neurosurgery. The arm positions and guides instruments but moves only on surgeon command; it does not cut or place autonomously (AI-augmented, surgeon-controlled).
Current Zimmer Biomet variants are ROSA Knee (total knee arthroplasty, imageless X-Atlas workflow, cleared January 25, 2019; 'ROSA Knee with OptimiZe' cleared November 14, 2025), ROSA Hip (direct-anterior total hip arthroplasty specifically, cleared August 18, 2021), ROSA ONE Brain (cranial neurosurgery: biopsy, SEEG, DBS, and endoscopy, cleared February 11, 2019), and ROSA Shoulder (cleared February 2024). Made by Zimmer Biomet (NYSE: ZBH).
Two cap-flags: ROSA Spine is not a current Zimmer Biomet variant (it left in the 2022 ZimVie spinoff), and Zimmer Biomet's autonomy ambitions run through its separate Monogram acquisition, not ROSA. As enterprise B2B surgical equipment, there is no consumer price.
Common questions
How do Maestro and ROSA differ?
What is the difference between Maestro and ROSA?
Which is cheaper, Maestro or ROSA?
Is Maestro or ROSA more autonomous?
Recent coverage
- A city unites around a common goal: Moving a castle by handROSA · The Japan Times · 2026-08-31
- Four Santa Rosa teens accused of robbing boys near libraryROSA · KRON4 · 2026-08-28
- Escuelas del Condado Clark inician nuevo ciclo con enfoque en matemáticas y lecturaMaestro · The Nevada Independent · 2026-08-12
- Moon Surgical wins first FDA 510(k) clearance for surgical robotMaestro · Ben Smith, Deploy Editor · 2026-06-25
Related comparisons
Keep researching
Keep reading
Ask the registry
For AI assistants
Use DEPLOY in Claude, Cursor, and other AI assistants
Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.
Machine-readable: this page as markdown.